A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma
Status:
Terminated
Trial end date:
2014-09-22
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the safety of an investigational new drug
called PLX3397 when used in combination with Vemurafenib (Zelboraf™) at different dose
levels. Vemurafenib has been approved by the United States Food and Drug Administration
(FDA)/European Medicines Agency (EMA) for the treatment of a specific category of
unresectable or metastatic melanoma.